BRPI0915367A2 - peptídeos e epítopos anti-p2x7 - Google Patents

peptídeos e epítopos anti-p2x7

Info

Publication number
BRPI0915367A2
BRPI0915367A2 BRPI0915367A BRPI0915367A BRPI0915367A2 BR PI0915367 A2 BRPI0915367 A2 BR PI0915367A2 BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 A2 BRPI0915367 A2 BR PI0915367A2
Authority
BR
Brazil
Prior art keywords
epitopes
peptides
Prior art date
Application number
BRPI0915367A
Other languages
English (en)
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Publication of BRPI0915367A2 publication Critical patent/BRPI0915367A2/pt
Publication of BRPI0915367B1 publication Critical patent/BRPI0915367B1/pt
Publication of BRPI0915367B8 publication Critical patent/BRPI0915367B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0915367A 2008-07-04 2009-07-03 peptídeo anti-p2x7 BRPI0915367B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
AU2008903451 2008-07-04
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Publications (3)

Publication Number Publication Date
BRPI0915367A2 true BRPI0915367A2 (pt) 2015-11-03
BRPI0915367B1 BRPI0915367B1 (pt) 2020-10-13
BRPI0915367B8 BRPI0915367B8 (pt) 2021-05-25

Family

ID=41465424

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915367A BRPI0915367B8 (pt) 2008-07-04 2009-07-03 peptídeo anti-p2x7

Country Status (12)

Country Link
US (3) US8597643B2 (pt)
EP (1) EP2318438B1 (pt)
JP (2) JP5701752B2 (pt)
KR (1) KR101701300B1 (pt)
CN (1) CN102143978B (pt)
AU (1) AU2009266430B2 (pt)
BR (1) BRPI0915367B8 (pt)
CA (1) CA2729868C (pt)
ES (1) ES2610225T3 (pt)
IL (2) IL210220A (pt)
NZ (1) NZ590146A (pt)
WO (1) WO2010000041A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434490C (en) 2001-01-17 2014-06-03 Intreat Pty Limited Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
CA2737126C (en) 2007-09-14 2018-05-01 Biosceptre International Limited Novel p2x7 epitopes
JP5624885B2 (ja) 2007-09-14 2014-11-12 バイオセプター・インターナショナル・リミテッド 細胞外体液中のプリン作動性（ｐ２ｘ）受容体
ES2610225T3 (es) 2008-07-04 2017-04-26 Biosceptre (Aust) Pty Ltd Péptidos y epítopos anti P2X7
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
AU2010336032C1 (en) 2009-12-24 2016-04-21 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
WO2016154683A1 (en) * 2015-04-02 2016-10-06 Biosceptre (Uk) Limited Pain treatment
WO2017041143A1 (en) 2015-09-11 2017-03-16 Ctm@Crc Ltd. Chimeric antigen receptors and uses thereof
EP3528789A4 (en) 2016-10-21 2020-06-24 Biosceptre UK Limited CYTOTOXIC PARTICLES
WO2019222796A1 (en) 2018-05-21 2019-11-28 Carina Biotech Pty Ltd Chimeric antigen receptors with modified linker domains and uses thereof
AU2022253547A1 (en) * 2021-04-08 2023-10-05 Biosceptre (Aust) Pty Ltd Methods for controlling immune cell activity
EP4587464A1 (en) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells
AU2023343786A1 (en) * 2022-09-14 2025-02-20 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells
EP4587465A1 (en) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
EP0760850A1 (en) 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
EP0907729A1 (en) 1996-04-30 1999-04-14 Smithkline Beecham Plc HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP2080802B1 (en) * 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU2001274902A1 (en) * 2000-12-06 2002-06-18 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CA2434490C (en) 2001-01-17 2014-06-03 Intreat Pty Limited Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
AU2002322192B2 (en) 2001-09-03 2008-05-01 Biosceptre International Limited Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
DK1473367T3 (da) 2003-04-17 2007-10-01 Affectis Pharmaceuticals Ag Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser
CA2607541A1 (en) * 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
JP5624885B2 (ja) 2007-09-14 2014-11-12 バイオセプター・インターナショナル・リミテッド 細胞外体液中のプリン作動性（ｐ２ｘ）受容体
CA2737126C (en) 2007-09-14 2018-05-01 Biosceptre International Limited Novel p2x7 epitopes
ES2610225T3 (es) 2008-07-04 2017-04-26 Biosceptre (Aust) Pty Ltd Péptidos y epítopos anti P2X7
ES2557456T3 (es) * 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
AU2010336032C1 (en) 2009-12-24 2016-04-21 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy

Also Published As

Publication number Publication date
CA2729868C (en) 2018-07-10
WO2010000041A1 (en) 2010-01-07
CN102143978A (zh) 2011-08-03
KR101701300B1 (ko) 2017-02-01
JP5701752B2 (ja) 2015-04-15
JP2015038144A (ja) 2015-02-26
BRPI0915367B8 (pt) 2021-05-25
US10238716B2 (en) 2019-03-26
IL210220A0 (en) 2011-03-31
JP2011526249A (ja) 2011-10-06
AU2009266430B2 (en) 2014-08-14
CA2729868A1 (en) 2010-01-07
IL210220A (en) 2016-04-21
BRPI0915367B1 (pt) 2020-10-13
US20160199442A1 (en) 2016-07-14
EP2318438A4 (en) 2012-11-21
IL232394A0 (en) 2014-06-30
AU2009266430A8 (en) 2011-03-10
KR20110031222A (ko) 2011-03-24
US9328155B2 (en) 2016-05-03
AU2009266430A1 (en) 2010-01-07
US20110110959A1 (en) 2011-05-12
US20140135475A1 (en) 2014-05-15
CN102143978B (zh) 2015-02-18
ES2610225T3 (es) 2017-04-26
EP2318438A1 (en) 2011-05-11
EP2318438B1 (en) 2016-11-02
NZ590146A (en) 2012-09-28
US8597643B2 (en) 2013-12-03
IL232394A (en) 2016-04-21

Similar Documents

Publication Publication Date Title
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
EP2276499A4 (en) ANTIGEN OF RECOMBINANT GLIADINE DEAMIDED
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
EP2377932A4 (en) ANTI-Siglec-15 ANTIBODY
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
IL212175B (en) Muc1* antibodies
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt) Anticorpo anti-cldn6
ATE543405T1 (de) Frisiergerät
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK2254806T3 (da) Lukning
HUE036081T2 (hu) Mirac proteinek
BRPI0820387A2 (pt) Agentes de ligação de wise e epítopos
HRP20151135T4 (hr) Novi i snažni peptidi mhc klase ii dobiveni od survivina
PT2813570T (pt) Resumo
DK3118220T3 (da) Protein
EP2361026A4 (en) FIXING PIECE
EP2207803A4 (en) Cd9-specific human antibodies
PT3045471T (pt) Resumo
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
DK2552434T3 (da) Peptider og anvendelse deraf
BRPI0918501A2 (pt) bolsa
BRPI0814971A2 (pt) Proteína
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI1010661A2 (pt) peptídeo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF